Smith Samantha Louise, Plant Darren, Eyre Stephen, Hyrich Kimme, Morgan Ann W, Wilson Anthony G, Isaacs John D, Barton Anne
Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, The University of Manchester.
National Institute for Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre.
Rheumatology (Oxford). 2017 Jun 1;56(6):1019-1024. doi: 10.1093/rheumatology/kew387.
The aim was to correlate protein concentrations of S100A9 in pretreatment serum samples with response to the tumour-necrosis factor (TNF) inhibitor drugs etanercept in a large UK replication cohort.
Pretreatment serum samples from patients with RA (n = 236) about to commence treatment with etanercept had S100A9 serum concentration measured using an ELISA. Following the experimental procedure, S100A9 concentrations were analysed with respect to EULAR response.
No evidence of association between S100A9 concentration and EULAR response to the TNF-inhibitor biologic drug etanercept was observed following multinomial logistic regression analysis (non-responder vs moderate responder, P = 0.957; and non-responder vs good responder, P = 0.316). Furthermore, no significant associations were observed when correlating pretreatment S100A9 concentrations with clinical parameters of disease activity (P > 0.05).
In the largest replication cohort conducted to date, no evidence for association was observed to support the use of S100A9 as a clinical biomarker predictive of response to the TNF-inhibitor biologic drug etanercept.
旨在将英国一个大型重复队列中，肿瘤坏死因子（TNF）抑制剂药物依那西普治疗前血清样本中S100A9的蛋白质浓度与治疗反应相关联。
对即将开始接受依那西普治疗的类风湿关节炎患者（n = 236）的治疗前血清样本，使用酶联免疫吸附测定法（ELISA）测量S100A9血清浓度。按照实验步骤，分析S100A9浓度与欧洲抗风湿病联盟（EULAR）反应的关系。
多项逻辑回归分析后，未观察到S100A9浓度与EULAR对TNF抑制剂生物药物依那西普的反应之间存在关联证据（无反应者与中度反应者相比，P = 0.957；无反应者与良好反应者相比，P = 0.316）。此外，将治疗前S100A9浓度与疾病活动的临床参数相关联时，未观察到显著关联（P > 0.05）。
在迄今为止进行的最大规模重复队列研究中，未观察到支持将S100A9用作预测TNF抑制剂生物药物依那西普反应的临床生物标志物的关联证据。
Zotero 插件